ARCHIVES

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

New Evidence Shows Polyp Removal Lowers Death Rate at 23-Year Follow-up

February 24, 2012

President’s Budget: $64 Million Cut for NCI, No Start On Year 2000 goals, Drop 240 Grants In 1985

February 8, 1985

Flavopiridol Plus Cisplatin Tested In Phase II Trial

October 26, 2007

Protocol Amendments Required For 98 NCI-Sponsored Trials

October 8, 2010

NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.

April 27, 2001

Centers Settle Into New Home, Face Old Problem; Five May Lose Grants, No Reprogramming Seen

November 17, 1989